ethoxy-ethyl-oxophosphanium | 998-80-1

• 分子结构分类: 有机化合物 - 有机磷化合物
• 英文名称: ethoxy-ethyl-oxophosphanium
• CAS: 998-80-1；59624-92-9；31355-98-3
• 化学式: C₄H₁₁O₂P
• 分子量: 122.1
• InChiKey: RKXDVGYSGPCUTF-UHFFFAOYSA-N

物化性质

• 沸点：
  140.7±23.0 °C(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  7
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  32.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  二乙胺 、 ethoxy-ethyl-oxophosphanium 在 四氯化碳 、 三乙胺 作用下， 以 苯 为溶剂， 生成 d-O-Ethylethylphosphonsaeurediethylamid
  参考文献：
  名称：

  Optically active phosphonic acid amidoesters

  摘要：

  DOI：

  10.1007/bf01143936
• 作为产物：
  描述：

  Ethyl-ethoxy-selenophosphinsaeure 在 镍 作用下， 生成 ethoxy-ethyl-oxophosphanium
  参考文献：
  名称：

  Chemical correlation of configuration of optically active selenophosphorus acids

  摘要：

  DOI：

  10.1007/bf00922511

文献信息

• [EN] PHOSPHONATE COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS<br/>[FR] COMPOSÉS DE PHOSPHONATE POUR LE TRAITEMENT DE TROUBLES IMMUNITAIRES ET INFLAMMATOIRES
  申请人：ACHILLION PHARMACEUTICALS INC

  公开号：WO2017035417A1

  公开（公告）日：2017-03-02

  Compounds, methods of use, and processes for making inhibitors of complement Factor D are provided comprising Formula I, I" and I''' or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduce the excessive activation of complement.

  提供含有公式I、I"和I'''或其药物可接受的盐或组合物的补体因子D抑制剂的化合物、使用方法和制备过程。本文所述的抑制剂针对因子D并抑制或调节补体级联。本文所述的因子D抑制剂减少了补体的过度激活。
• Method for producing dialkylphosphinic acids and esters and salts thereof by means of allyl alcohols-acroleins and use thereof
  申请人：Hill Michael

  公开号：US09139714B2

  公开（公告）日：2015-09-22

  The invention relates to a method for producing mono-carboxyfunctionalized dialkylphosphinic acids and esters and salts thereof, characterized in that a) a phosphinic acid source (I) is reacted with olefins (IV) to yield an alkylphosphonic acid, salt or ester (II) thereof in the presence of a catalyst A, b) the thus obtained alkyl phosphonic acid, salt, salt or ester (II) thereof is reacted with compounds of formula (V) and/or (VI′) to yield mono-functionalized dialkylphosphinic acid derivatives (VI) and/or (VI′) in the presence of a catalyst B, and c) the thus obtained mono-functionalized dialkylphosphinic acid derivatives (VI) and/or (VI′) are reacted to yield a mono-carboxyfunctionalized dialkylphosphinic acid derivative (III) in the presence of a catalyst C, wherein R1, R2, R3, R4, R5, R6, R7 are the same or different and stand independently of each other, among other things, for H1 C1-C18 alkyl, C6-C18 aryl, C6-C18 aralkyl, C6-C18 alkylaryl, and X and Y are the same or different and stand independently of each other for H, C1-C18 alkyl, C6-C18 aryl, C6-C18 aralkyl, C6-C18 alkylaryl, Mg, Ca, Al, Sb, Sn, Ge, Ti, Fe, Zr, Zn, Ce, Bi, Sr, Mn, Cu, Ni, Li, Na, K and/or a protonized nitrogen base, and the catalysts A and C are formed by transition metals and/or transition metal compounds and/or catalyst systems composed of a transition metal and/or a transition metal compound and at least one ligand, and catalyst B is formed by compounds forming peroxides and/or peroxo compounds and/or azo compounds and/or alkali metals and/or alkaline earth metals, alkali hydrides, alkaline earth hydrides and/or alkali alcoholates and alkaline earth alcoholates.

  该发明涉及一种生产单羧基功能化二烷基膦酸和酯及其盐的方法，其特征在于a) 在催化剂A的存在下，将膦酸源(I)与烯烃(IV)反应，得到烷基膦酸、盐或酯(II)，b) 将所得的烷基膦酸、盐或酯(II)与式(V)和/或(VI')的化合物反应，得到单官能化的二烷基膦酸衍生物(VI)和/或(VI')，在催化剂B的存在下，c) 将所得的单官能化的二烷基膦酸衍生物(VI)和/或(VI')在催化剂C的存在下反应，得到单羧基功能化的二烷基膦酸衍生物(III)，其中R1、R2、R3、R4、R5、R6、R7相同或不同且独立地代表H1 C1-C18烷基、C6-C18芳基、C6-C18芳基烷基、C6-C18烷基芳基，X和Y相同或不同且独立地代表H、C1-C18烷基、C6-C18芳基、C6-C18芳基烷基、C6-C18烷基芳基、Mg、Ca、Al、Sb、Sn、Ge、Ti、Fe、Zr、Zn、Ce、Bi、Sr、Mn、Cu、Ni、Li、Na、K和/或质子化氮碱基，催化剂A和C由过渡金属和/或过渡金属化合物和/或由过渡金属和/或过渡金属化合物以及至少一种配体组成的催化剂系统形成，催化剂B由形成过氧化物和/或过氧化物化合物和/或偶氮化合物和/或碱金属和/或碱土金属、碱金属氢化物、碱土金属氢化物和/或碱金属醇酸盐和碱土金属醇酸盐的化合物形成。
• [EN] ETHER COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS<br/>[FR] COMPOSÉS ÉTHER POUR LE TRAITEMENT DE TROUBLES MÉDICAUX
  申请人：ACHILLION PHARMACEUTICALS INC

  公开号：WO2017035355A1

  公开（公告）日：2017-03-02

  Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an ether substituent (R32) are provided. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduce the excessive activation of complement.

  提供了一种包括化合物、使用方法和制备过程的抑制补体因子D的方法，其中所述方法包括化合物I的结构，或其药用盐或组合物，其中A组上的R12或R13是醚取代基（R32）。本文描述的抑制剂靶向因子D并抑制或调节补体级联反应。本文描述的因子D抑制剂减少了补体的过度激活。
• Substituted propane-phosphinic acid compounds
  申请人：Ciba-Geigy Corporation

  公开号：US05064819A1

  公开（公告）日：1991-11-12

  Compounds of the formula I ##STR1## wherein R denotes an aliphatic, cycloaliphatic, cycloaliphatic-aliphatic or araliphatic radical having 2 or more carbon atoms, and wherein one of the groups R.sup.1, R.sup.2 and R.sup.3 represents hydrogen or an aliphatic, cycloaliphatic, araliphatic or aromatic radical, another one of R.sup.1, R.sup.2 and R.sup.3 is hydrogen or, in the case of R.sup.1 and R.sup.2, is hydroxy, and the remaining one of R.sup.1, R.sup.2 and R.sup.3 is hydrogen, or wherein R denotes methyl, R.sub.1 denotes hydrogen or hydroxy, R.sub.2 denotes an aromatic radical and R.sub.3 represents hydrogen, and their salts have GABA.sub.B -antagonistic properties and can be used as GABA.sub.B -antagonists. They are obtained when in a compound of formula II ##STR2## in which R, R.sup.1, R.sup.2 and R.sup.3 have their previous significances, Z represents --NH.sub.2 and R.sup.4 denotes a hydroxy-protective group R.sup.5 or, when R.sup.1 and R.sup.3 denote hydrogen and R.sup.2 denotes hydrogen or alkyl, denotes an alkali metal or ammonium ion R.sup.6, or Z represents a protected or latent amino group Z.sup.0 and R.sup.4 denotes hydrogen or a hydroxy-protective group R.sup.5, any group R.sup.5 or R.sup.6 is replaced by hydrogen, and/or any group Z.sup.0 is converted into --NH.sub.2.

  公式I的化合物##STR1##其中R表示具有2个或更多碳原子的脂肪族、环脂族、环脂族-脂肪族或芳基脂肪基，其中R.sup.1、R.sup.2和R.sup.3中的一个代表氢或脂肪族、环脂族、芳基脂肪基或芳香族基，R.sup.1、R.sup.2和R.sup.3中的另一个是氢或在R.sup.1和R.sup.2的情况下是羟基，而R.sup.1、R.sup.2和R.sup.3中的剩余一个是氢，或者R表示甲基，R.sub.1表示氢或羟基，R.sub.2表示芳基，R.sub.3表示氢，它们的盐具有GABA.sub.B-拮抗性质，可用作GABA.sub.B-拮抗剂。当在公式II的化合物中获得它们##STR2##其中R、R.sup.1、R.sup.2和R.sup.3具有其先前的含义，Z表示--NH.sub.2，R.sup.4表示羟基保护基R.sup.5或者当R.sup.1和R.sup.3表示氢且R.sup.2表示氢或烷基时，表示碱金属或铵离子R.sup.6，或者Z表示受保护或潜在的氨基Z.sup.0且R.sup.4表示氢或羟基保护基R.sup.5，任何一个R.sup.5或R.sup.6基团被氢取代，和/或任何一个Z.sup.0基团被转化为--NH.sub.2。
• [EN] CINNOLINIUM COMPOUNDS FOR USE IN A METHOD OF CONTROLLING UNWANTED PLANT GROWTH<br/>[FR] COMPOSÉS DE CINNOLINE DESTINÉS À ÊTRE UTILISÉS DANS UN PROCÉDÉ DE LUTTE CONTRE LA CROISSANCE INDÉSIRABLE DE PLANTES
  申请人：SYNGENTA CROP PROTECTION AG

  公开号：WO2020164970A1

  公开（公告）日：2020-08-20

  The present invention relates to herbicidally active cinnolinium derivatives of formula (I), as well as to processes and intermediates used for the preparation of such derivatives. The invention further extends to herbicidal compositions comprising such derivatives, as well as to the use of such compounds and compositions in controlling undesirable plant growth: in particular the use in controlling weeds, in crops of useful plants.

  本发明涉及式(I)的具有除草活性的喹啉盐衍生物，以及用于制备这种衍生物的过程和中间体。该发明进一步涉及包含这种衍生物的除草剂组合物，以及在控制不良植物生长方面使用这些化合物和组合物，特别是在有用植物作物中控制杂草的使用。